## **Survivorship Protocol List**

## Afrac. Cancer & Blood Disorders Center CHILDREN'S HEALTHCARE OF ATLANTA

## **July 2021**

Survivorship protocols				
Study	Clinical trial name	Phase/type	Age	
COG ALTE1631	ALTE1631, A Randomized Web-based Physical Activity Intervention among Children and Adolescents with Acute Lymphoblastic Leukemia <a href="https://clinicaltrials.gov/ct2/show/NCT03223753">https://clinicaltrials.gov/ct2/show/NCT03223753</a>	NA	≥8 to <u>&lt;</u> 16 yr	
COG ALTE03N1	Key Adverse Events after Childhood Cancer (cardiac, stroke, secondary malignancies) closed to AVN patients as of 11-26-08 https://clinicaltrials.gov/ct2/show/NCT00082745	Non- therapeutic	<u>&lt;</u> 21 yr at dx	
COG ALTE05N1	Umbrella Long-TermFollow-Up Protocol https://clinicaltrials.gov/ct2/show/NCT00736749	Non- therapeutic	Any age	
COG ALTE11C2	ALTE11C2, Health Effects after Anthracycline and Radiation Therapy (HEART): Dexrazoxane and Prevention of Anthracycline-related Cardiomyopathy https://clinicaltrials.gov/ct2/show/NCT01790152	Non- therapeutic	Any age	
COG ALTE15N2	ALTE15N2: LEAHRN ( <u>Late Effects After High-Risk Neuroblastoma</u> ) Study <a href="https://clinicaltrials.gov/ct2/show/NCT03057626">https://clinicaltrials.gov/ct2/show/NCT03057626</a>	Non- therapeutic	<u>≥</u> 5 yr	
COG ALTE16C1	ALTE16C1: Effects of Modern Chemotherapy Regimens on Spermatogenesis and Steroidogenesis in Adolescent and Young Adult (AYA) Survivors of Osteosarcoma https://clinicaltrials.gov/ct2/show/NCT03206450	Non- therapeutic	Males ≥18 to ≤50 yr previously treated on AOST0331 or CCG7921 (INT0133, POG9351)	
LETKI	LETKI: Late Effects after Tyrosine Kinase Inhibitor Therapy in Children and Adolescents	Non- therapeutic	<u>&lt;</u> 21 yr	
ccss	Childhood Cancer Survivorship Study <a href="https://clinicaltrials.gov/ct2/show/NCT01120353">https://clinicaltrials.gov/ct2/show/NCT01120353</a>	Non- therapeutic	Any age, but diagnosed at <21 yr	
CAYACSS	Long-termFollow-up of Childhood, Adolescent, and Young Adult Cancer Survivors (CAYACSS)	Non- therapeutic	An y age but must be ≤30 yr at dx	
Surv Engagement	CURE Patient Engagement: Evaluating Patient Engagement in Survivor Healthcare after Childhood Cancer Treatment  Aim 1: Parents/caregivers of ped survivors 1 to 17 yr off treatment for 12-18 mo—closed to accrual	Non- therapeutic	[See col 2]	

	Aim 2: Parents/caregivers of ped survivors <19 yr not seen in Surv Clinic in 3 yr, or those who have never been to Surv Clinic		
Surv Transfer Outcomes	Predicting Childhood Cancer Survivors' Transition Readiness & Transfer Outcomes	Non- therapeutic	18 to 25 yr
Surv E-Screen	Evaluating Electronic Psychosocial Screening in Pediatric Oncology	Non- therapeutic	<u>≥</u> 2 yr
QOL Targeted Tx Brain Tumors	Health-related Quality of Life Outcomes during Molecularly Targeted Therapy for the Treatment of High-Risk Pediatric Brain Tumors	Non- therapeutic	<u>&lt;</u> 21 yr
Maximizing HPV Vaccine	Implementation of a Provider-Focused Intervention for Maximizing HPV Vaccine Uptake in Young Cancer Survivors receiving Follow-Up Care in Pediatric Oncology Practices: A Cluster-Randomized Trial <a href="https://clinicaltrials.gov/ct2/show/NCT04469569">https://clinicaltrials.gov/ct2/show/NCT04469569</a>	Non- therapeutic	Healthcare Providers